Results 41 to 50 of about 6,415,892 (312)

Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) [PDF]

open access: yes, 2023
The Monogenic Network of the Global Parkinson’s Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson’s disease (PD) and to improve our understanding of already identified ...
Heutink, Peter   +77 more
core   +2 more sources

Additional file 1: of Surgical outcomes of spinal fusion for osteoporotic thoracolumbar vertebral fractures in patients with Parkinsonâ s disease: what is the impact of Parkinsonâ s disease on surgical outcome?

open access: yes, 2019
The assessment Scale Proposed by the Japanese Orthopaedic Association. The Japanese Orthopaedic Association Scoring system (JOA score) consists of 2 categories (subjective and objective symptoms), ranging from 0 (worst condition) to 15 (best condition). (DOCX 22 kb)
Watanabe, Kei   +68 more
openaire   +1 more source

Auditory observation of stepping actions can cue both spatial and temporal components of gait in Parkinson's disease patients [PDF]

open access: yes, 2014
Objectives: A common behavioural symptom of Parkinson’s disease (PD) is reduced step length (SL). Whilst sensory cueing strategies can be effective in increasing SL and reducing gait variability, current cueing strategies conveying spatial or temporal ...
Young, William R.   +5 more
core   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

open access: yesFEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Topic Review:: Levodopa/Receptor Ligands in Parkinson’s Disease

open access: yes, 2021
Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as well as ...
Gianfabio Giorgioni   +2 more
core   +1 more source

Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation

open access: yesnpj Parkinson's Disease
Understanding medium spiny neuron (MSN) physiology is essential to understand motor impairments in Parkinson’s disease (PD) given the architecture of the basal ganglia.
Quyen B. Do   +13 more
doaj   +1 more source

Measuring anxiety in Lewy Body Disease – Which scale to choose?

open access: yesClinical Parkinsonism & Related Disorders, 2021
Background: Anxiety is among the most prevalent mood disorders in Lewy Body Disease (LBD) (i.e., Parkinson’s disease (PD), Dementia with Lewy bodies DLB), and those at-risk for developing LBD (e.g. isolated REM Sleep Behaviour Disorder (iRBD)).
Isabel Paniak   +2 more
doaj   +1 more source

MOESM1 of Brain mediators of systemic oxidative stress on perceptual impairments in Parkinsonâ s disease

open access: yes, 2015
Additional file 1. Detail T1-weighted structural MRI image processing procedures.
Lin, Wei-Che   +12 more
openaire   +1 more source

The potential role of dietary polyphenols in Parkinson’s disease [PDF]

open access: yes, 2011
Cumulative evidence now suggests that the abnormal aggregation of the neuronal protein alpha-synuclein is critically involved in the pathogenesis of synucleinopathies, of which Parkinson’s disease (PD) is the most prevalent. Development of neuropathology
Vassallo, Neville   +1 more
core  

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy